This article aims to instruct you on how to swiftly locate related sequences via a simple one-click method, using the target name.

This article summarized the latest R&D progress of Triptolide, the Mechanism of Action for Triptolide, and the drug target R&D trends for Triptolide.

Kyverna Therapeutics reveals FDA approval for Phase 2 study of KYV-101, a complete human CD19 CAR T-Cell treatment for Myasthenia Gravis.

On Oct 31, 2023, the latest clinical data of MDNA11 monotherapy in a phase 1/2 study on advanced solid tumors was reported at SITC Congress, showing potential efficacy for future research.

Latest news on PACIFIC-2 Phase III study of Imfinzi given along with platinum-based chemo and radiotherapy for Stage III non-small cell lung cancer that can't be surgically removed.

This article summarized the latest R&D progress of Voglibose, the Mechanism of Action for Voglibose, and the drug target R&D trends for Voglibose.

Mozart Therapeutics shares trial results for MTX-101, a unique dual-action CD8 Treg adjuster used for treating autoimmune diseases, at the 2023 American College of Rheumatology Convergence.

Chk inhibitors can hinder the self-repair of tumor cells, thereby achieving the goal of enhancing the killing of tumor cells.

SCG Cell Therapy reports that SCG101 enhances tumor reactions and maintains consistent antiviral actions in patients having advanced hepatocellular carcinoma linked to HBV.

BNT116 is an intravenously administered RNA-lipoplex therapeutic cancer vaccine comprising six RNAs each encoding a tumor-associated antigen (TAA) frequently expressed in non-small cell lung cancer (NSCLC).

Ionetix Corporation has publicized that it has entered into a supply contract for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer.

This article summarized the latest R&D progress of Vosoritide, the Mechanism of Action for Vosoritide, and the drug target R&D trends for Vosoritide.